WisdomTree U.S. AI Enhanced Value Fund (ARCA: AIVL)

에 대한 최신 뉴스 WisdomTree U.S. AI Enhanced Value Fund (ARCA:AIVL)

Industrials

Financial Services

Healthcare

Technology

Utilities

Consumer Defensive

Energy

Real Estate

Communication Services

Basic Materials

Consumer Cyclical

Other

The Fund is actively managed and seeks to achieve its investment objective by investing primarily in equity securities selected from a universe of U.S. equities that exhibit value characteristics (the Parent Universe) based on the selection results of a proprietary, quantitative artificial intelligence (AI) model developed by Voya Investment Management Co. LLC (Voya IM or the Sub-Adviser). AI refers to the simulation of human intelligence by machines. Machine learning is a subset of AI that refers to a machines ability to learn and improve from experience automatically without being explicitly programmed.

Exxon Mobil Corp

Intercontinental Exchange Grp Usd0.01

Otis Worldwide Corporation

MEDTRONIC

Fortive Corp

Comcast Corporation

Bank Of America Corp.

Nasdaq Inc.

Abbott Laboratories

Ppl Corp. [ppl]

Wells Fargo &amp; Co

Intercontinentalexchange Group

Roper Technologies Inc (industrials)

NISOURCE INC

Teledyne Technologies Inc

Arconic Inc

Cme Group Inc

Rtx Corpcommon Stock

Centerpoint Energy Inc 144A PIPE Private Placement

Us Bancorp

WisdomTree US AI Enhanced Value Fund

Graph,Chart,Of,Stock,Market,Investment,Trading.,Financial,Chart,With

Equities

Large Cap

AIVL

AMZN

iShares Trust S&P Global Telecommunications Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

MSFT

ONLN

RSPG

지난주 댄 로브(Dan Loeb)가 이끄는 &#39;행동주의 헤지펀드&#39; 서드포인트의 포트폴리오에 포함된 여러 주요 기업의 실적 보고서가 발표되었다. 2024년 4분기 기준 여러 섹터의 주요 종목에 대한 새로운 인사이트가 제공되었다. 

아마존·메타·마이크로소프트 실적, &#39;행동주의 헤지펀드&#39; 서드포인트의 포트폴리오에 의미하는 바는?

WisdomTree U.S. AI Enhanced Value Fund

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are falling Thursday morning after the company announced a proposed <a href="https://www.benzinga.com/pressreleases/25/05/b45282745/hims-hers-health-inc-announces-proposed-convertible-senior-notes-offering-to-accelerate-global-exp">convertible senior notes offering</a>.
What Happened: Hims &amp; Hers Health announced plans on Thursday to offer $450 million&nbsp;worth of convertible senior notes due 2030 in a private offering to institutional investors. The company also expects to grant the initial purchasers a 13-day window to purchase up to an additional $67.5 million of the notes.
Hims &amp; Hers Health intends to use the proceeds to help accelerate global expansion through organic growth and strategic acquisitions, as well as for general corporate purposes. The proceeds will also help support the company&#8217;s technology team to expand its data pipeline, develop AI tools and advance personalized treatments, improving the consumer healthcare experience.
Hims &amp; Hers Health announced that it appointed Mo Elshenawy to lead technology at the company. As the new chief technology officer, Elshenawy will help accelerate the company&#8217;s vision to build a next-generation healthcare platform powered by AI.
&#8220;The future of care connects diagnosis, treatment, and delivery seamlessly, and in a way that feels tailored to the individual. We believe AI is an important way to standardize high-quality care globally to millions of people, regardless of their income or where they live,&#8221; said Andrew Dudum, CEO and co-founder of Hims &amp; Hers.
&#8220;Our ambition to build a platform that offers access to safe, high-quality personalized care requires an accelerated investment in technology, and Mo is just the leader to drive that work.&#8221;
Hims &amp; Hers Health shares have been trending higher this week after the company reported <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">better-than-expected financial results</a> for the first quarter after the market close on Monday.
Total revenue jumped 111% on a year-over-year basis as subscribers grew to 2.4 million in the quarter, up 38% year-over-year.&nbsp;
Hims &amp; Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million. The company said it continues to expect full-year 2025 revenue in the range of $2.3 billion to $2.4 billion versus estimates of $2.32 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
"We're starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes," Dudum said earlier this week.
HIMS Price Action: <a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a> were down 1.41% at $51.53 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45282981/top-3-health-care-stocks-that-could-sink-your-portfolio-in-q2">Top 3 Health Care Stocks That Could Sink Your Portfolio In Q2</a></li>
</ul>
Photo: Lori Butcher/Shutterstock.

News

Offerings

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock Is Sliding Thursday: What's Going On?

<a href="https://www.reuters.com/business/energy/us-russia-explore-ways-restore-russian-gas-flows-europe-sources-say-2025-05-08/">https://www.reuters.com/business/energy/us-russia-explore-ways-restore-russian-gas-flows-europe-sources-say-2025-05-08/</a>
&nbsp;

Macro Economic Events

Global

Economics

'US, Russia Explore Ways To Restore Russian Gas Flows To Europe, Sources Say' - Reuters News

Truist Securities analyst Michael Swartz maintains Acushnet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a Hold and raises the price target from $64 to $65.

Price Target

Analyst Ratings

GOLF

Truist Securities Maintains Hold on Acushnet Holdings, Raises Price Target to $65

Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) reported better-than-expected earnings for the first quarter, but <a href="https://www.benzinga.com/quote/G/earnings">lowered its FY25 earnings outlook.</a>
The company posted quarterly earnings of 84 cents per share which beat the analyst consensus estimate of 79 cents per share. The company reported quarterly sales of $1.21 billion which met the analyst consensus estimate.
&#8220;We entered 2025 with strong momentum. Revenue in the first quarter grew 8% year-over-year with Data-Tech-AI revenue up 12%, on a constant currency basis, driving adjusted EPS growth of 16%. Looking ahead, our deep process and domain expertise remains a key competitive advantage as we partner with clients to optimize costs and accelerate transformation using AI and other advanced technologies,&#8221; said Balkrishan &#8220;BK&#8221; Kalra, Genpact&#8217;s President &amp; CEO. &#8220;Although the operating environment has changed since the beginning of the year, the strength of our business model and resilience of our strategy remain clear. We believe our continued focus on accelerating innovation, deepening client relationships, and driving results positions us to accelerate growth in the future.&#8221;
Genpact lowered its FY2025 GAAP EPS guidance from $3.04-$3.11 to $2.90-$3.01. The company also slashed its FY2025 adjusted EPS guidance from $3.52-$3.59 to $3.41-$3.52.
Genpact shares fell 0.3% to close at $49.55 on Wednesday.
These analysts made changes to their price targets on Genpact following earnings announcement.
<ul>
<li>Needham analyst Mayank Tandon maintained Genpact with a Buy and lowered the price target from $55 to $50.</li>
<li>Baird analyst David Koning maintained the stock with a Neutral and lowered the price target from $56 to $50.</li>
</ul>
Considering buying G stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-1024x583.png" alt="" class="wp-image-908000" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Genpact Analysts Cut Their Forecasts After Q1 Results

Experienced partner to launch rollout of up to hundreds of GPS monitoring units from SuperCom's PureSecurity Suite
TEL AVIV, Israel, May 8, 2025 /PRNewswire/ -- SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>),&nbsp;a global provider of secured solutions for the e-Government, IoT, and cybersecurity sectors, today announced that it has signed a new contract with a seasoned electronic monitoring service provider based in Canada. This agreement marks another milestone in SuperCom's North American expansion and reinforces its growing global presence in the electronic monitoring (EM) market.

SPCB

SuperCom Signs New Contract With Electronic Monitoring Service Provider Based In Canada

United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) reported $7.00 million in sales this quarter. This is a 147.26 percent increase over sales of $2.83 million the same period last year.

UAMY

United States Antimony Q1 Sales $7.00M Up From $2.83M YoY

Baird analyst Jeffrey Meuler maintains Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) with a Outperform and raises the price target from $320 to $335.

VRSK

Baird Maintains Outperform on Verisk Analytics, Raises Price Target to $335

<a href="https://www.globenewswire.com/Tracker?data=Stnp4f2xkXdpdYz1XNTV4fG-mxc9cEb67No2uRpooNh77GiFKyX2y60dQdr3a9jkkyIMy7bDRsxTwMCGhxS3sA==">Beam Global</a>, (Nasdaq:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=y7LjIf-CxUruvr0IxihRYXPESjxXfpb8ywora3Cep3nWv8Clrr9wKrA4fm9JOkmdukwgO-3TdYgV2zaMvW8FYkSsL46rj-76yuKs3xGAaMQ=">BEEM</a>), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced a broad range of new orders for its <a href="https://www.globenewswire.com/Tracker?data=GB9E4tY8IOq_Pe44uZ7AmSktSlndoUSRFoQKwipvMlplLN-blYPEYxZRs214fpZgdsPYy69bGg6Y3rDo_Dt41cn0wRIf6Tsyn_9jQMNcUgU=">EV ARC&#x2122;</a> off-grid solar-powered charging units, despite a reduction in federal demand. The 23% quarter-over-quarter increase in orders reflects growing demand for clean, resilient infrastructure solutions across a wide variety of sectors and regions.
Recent orders were placed by a mix of municipal and county governments, state and federal agencies, environmental organizations, and private sector companies including those in construction, clean energy, and technology. The orders came from multiple states including California, Arizona, Colorado, Florida, Michigan, and Washington.

Contracts

BEEM

Beam Global Reports 23% QoQ Surge In Orders For EV ARC Off-Grid Solar Charging Units

WIIM

WRBY

WRBY stock has given up its prior loss. Warby Parker shares were trading lower after the company missed Q1 estimates and lowered its FY25 sales guidance.

Baird analyst David Koning maintains Verra Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) with a Outperform and raises the price target from $27 to $28.

VRRM

Baird Maintains Outperform on Verra Mobility, Raises Price Target to $28

Use of AI and machine learning accelerates identification of patient groups whose care can be improved
First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy&#xAE; or Ozempic&#xAE;
Initial findings support opportunities to improve diagnosis and treatment and demonstrate isomyosamine's potential to impact quality of life in a general practice population
TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy.
In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development.

Biotech

General

TNFA

TNF Pharmaceuticals And Renova Health Announce Initial Results From AI-Driven Study Of 30K Patients On GLP-1 Agonists, Highlighting Potential Of Isomyosamine To Improve Diagnosis, Preserve Muscle Mass, And Enhance Treatment For Inflammatory Conditions

VTRS

Viatris shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Wells Fargo analyst Cerena Chen maintains Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Overweight and lowers the price target from $40 to $35.

AMPH

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $35

Baird analyst Jon Vruwink maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Neutral and raises the price target from $84 to $90.

QTWO

Baird Maintains Neutral on Q2 Holdings, Raises Price Target to $90

ABEV

Ambev shares are trading higher following Q1 financial results.

<a href="https://www.globenewswire.com/Tracker?data=u3BgzIQ7W6gaaNsksAWiO5_3u-zGn7J115dtO8yObSQEK9bGZmyaw8whtfwqqSWJvLvOCmDKwvV5GFDJ068VW7XpxC8bJsBjdYwdOBKIVe0GVioTN9GdkfTPsBKaKxGc">SS Innovations International, Inc.</a> (the "Company" or "SS Innovations") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company is planning to submit a De Novo Classification Request to the U.S. Food and Drug Administration (the "FDA") for the SSi Mantra 3 surgical robotic system (the "SSi Mantra 3") in July 2025.&nbsp; &nbsp;
If approved by the FDA, the SSi Mantra 3 would be cleared to market in the United States. Submission of the De Novo Classification Request does not guarantee FDA approval.
Since the Company began the sale of its system in August 2022 it has installed a total of 80 SSi Mantra robotic surgical systems in 75 hospitals and over 3,800 surgeries have been performed, including over 200 robotic cardiac surgeries. The SSi Mantra 3 version was launched in June 2024, and the Company has already installed 37 systems that have been utilized to perform more than 750 multispecialty robotic surgical procedures, including 70 cardiac cases, with no device related mortality, injury or complications.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Real world clinical data, validated by a leading contract research organization ("CRO"), supports the ability of the SSi Mantra 3 to safely perform a wide variety of surgical procedures. The planned submission of the SSi Mantra 3 to the FDA will include an application for multispecialty indications including urology, gynecology, general surgery, and thoracic and cardiac surgery.

SSII

SS Innovations To Submit De Novo Request To FDA In July 2025 For SSi Mantra 3 Surgical Robotic System

Bank of America is doubling down on its call that the Federal Reserve will not cut interest rates in 2025, underscoring the central bank's growing discomfort with a dual threat of rising inflation and unemployment revealed at <a href="https://www.benzinga.com/topic/federal-reserve">this week's policy meeting.</a>
In a note shared Thursday, BofA economist Aditya Bhave said the key takeaway from the May Federal Open Market Committee meeting was "an upgrade to the Fed&#8217;s assessment of economic uncertainty." 
Bhave referred to two new lines in the Fed's statement: first, that uncertainty "has increased further," and second, "risks of higher unemployment and higher inflation have risen."
<h3 class="wp-block-heading">Hawkish Tilt As Fed Acknowledges Stagflation Risks</h3>
While the Fed kept rates unchanged at 4.25%-4.50%, Chair Jerome Powell's press conference took a cautious, hawkish tone compared to March.
Powell repeatedly emphasized the central bank's comfort with staying on hold and made clear that the Fed would not act preemptively—unlike in 2019 when it delivered three rate cuts as inflation was running well below target.
That's not the case today. Core inflation has exceeded the Fed's 2% target for four straight years, giving policymakers far less room to maneuver. 
Bhave said Powell's message was clear: "Uncertainty is high, and the Fed is comfortable staying on hold until there is greater clarity."
<h3 class="wp-block-heading">Higher Bar For Cuts, Markets Start To Adjust</h3>
According to Bhave, this approach means the hurdle for a June cut is now significantly higher. 
Market expectations have already begun to reflect that shift. 
The CME FedWatch tool shows that the probability of a June rate cut tumbled to 16% on Thursday &#8211; down from 28% before Powell's remarks. The chances of a July move are 65%, down from 92% a week ago.
BofA's base case assumes a steady labor market paired with renewed inflationary pressures—conditions that effectively rule out any Fed rate cuts.
"If our base case of a steady labor market and rising inflation is correct, we don&#8217;t see a path to cuts in 2025," Bhave said.
<h3 class="wp-block-heading">Implications For Markets</h3>
BofA rate strategist Mark Cabana said front-end Treasury yields could move higher as investors increasingly price out near-term rate cuts. He also recommends staying underweight in longer-dated Treasuries, where issuance—particularly in the 30-year tenor—continues to exceed demand.
BofA maintains a broadly bearish stance on the U.S. dollar despite adopting a more hawkish-than-consensus view on the rate outlook. Cabana said the dollar remains "notably dislocated from short-term rate differentials," and that this misalignment is unlikely to correct through subtle shifts in Fed language alone.
"We remain broadly dollar-bearish, and negative sentiment more broadly has increased over the past month, with many re-thinking broader allocations to U.S. assets and/or FX hedges," the investment bank said.
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – has fallen 8% year-to-date, on track for its worst year since 2017. 
 Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45269703/stagflation-emerges-as-key-economic-risk-to-federal-reserve-policy-economists-warn">Stagflation Emerges As Key Risk To Fed Policy, Economists Warn: &#8216;We&#8217;re Grappling With A Rare Trifecta&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Bonds

Currency ETFs

Forex

Treasuries

Econ #s

ETFs

PowerShares DB US Dollar Index Bullish Fund

Forget Rate Cuts This Year, Bank Of America Warns After Powell's Hawkish Tone

CART

Maplebear shares are trading lower after the company announced the resignation of its CEO.

Baird analyst Rob Oliver maintains ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) with a Neutral and lowers the price target from $7 to $5.

ONTF

Baird Maintains Neutral on ON24, Lowers Price Target to $5

Banco Bradesco shares are trading higher following a year-over-year increase in Q1 sales results.

지난주 댄 로브(Dan Loeb)가 이끄는 &#8216;행동주의 헤지펀드&#8217; 서드포인트의 포트폴리오에 포함된 여러 주요 기업의 실적 보고서가 발표되었다. 2024년 4분기 기준 여러 섹터의 주요 종목에 대한 새로운 인사이트가 제공되었다.
아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): 댄 롭은 아마존 지분을 2024년 3분기 370만 주에서 <a href="https://www.benzinga.com/news/large-cap/25/02/43673006/dan-loebs-amazon-stake-moves-a-look-at-his-trading-shifts" target="_blank" rel="noopener">2024년 4분기</a> 345만 주로 줄였다.
<ul>
<li>5월 1일, 아마존은  1분기 순 매출이 1557억 달러로, 월가의 컨센서스 추정치 1550억 달러를 초과하고, 주당순이익(EPS)은 1.59달러로, 월가의 컨센서스 추정치인 1.36달러를 초과했다고 발표했다.</li>
<li>아마존은 2분기 순매출 1,590억~1,640억 달러 가이던스를 제시했는데, 이는 7%~11% 증가한 수치로, <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noopener">시장 전망치 1,691억 달러</a> 대비 높은 수치다.</li>
<li>아마존은 환율, 지정학적 조건의 변화, "관세 및 무역 정책" 등 "예측할 수 없는" 항목에 따라 지침이 달라질 수 있다고 말했다.</li>
<li>앤디 재시(Andy Jassy) CEO는 팬데믹 시대를 연상시키는 소비자 행동의 잠재적 변화를 예측하면서 이커머스 대기업인 아마존이<a href="https://www.benzinga.com/markets/25/05/45158172/andy-jassy-predicts-pandemic-like-consumer-shifts-says-amazon-is-maniacally-focused-on-keeping-prices-low" target="_blank" rel="noopener">경제성으을 두 배로 높이고 있다</a>고 주장했다.</li>
<li>JP모건 애널리스트인 더그 앤머스는 아마존의 1분기 매출과 영업이익이 거시경제나 관세 문제로 인한 큰 부정적 영향 없이 가이던스의 상단을 상회했다고 강조했다. 또한 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45172067/amazon-delivers-q1-on-the-steady-side-of-ok-as-analysts-highlight-aws-ai-demand" target="_blank" rel="noopener">사상 최고치</a>를 기록한 AWS 마진에 대해서도 언급했다.</li>
<li>로젠블랫 애널리스트인 바튼 크로켓은 아마존의 1분기를 "괜찮은 편"이라고 평가하면서도 "곧 부과되기 시작할 수 있는" 관세로 인한 영향 가능성을 지적했다.</li>
<li>RBC 캐피탈 마켓츠 애널리스트인 브래드 에릭슨도 AWS 수주잔고의 성장을 강조하며 <a href="https://www.benzinga.com/25/05/45163955/these-analysts-boost-their-forecasts-on-amazon-following-upbeat-q1-results" target="_blank" rel="noopener">하반기</a>에 가속도가 붙을 것으로 예상했다.</li>
<li>전년 동기 대비(YTD) 아마존 주가는 약 17.11% 하락한 반면, 같은 기간 동안 ProShares 온라인 리테일 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>)는 약 4.70% 하락했다.</li>
</ul>
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): 2월 14일에 발표된 13F 서류에 따르면, 댄 로브는 2024년 3분기 545,000주에서 <a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noopener">22% 증가한</a> 665,000주로 페이스북의 모회사 메타의 지분을 늘렸다.
<ul>
<li>메타의 1분기 매출은 423억 1천만 달러로 애널리스트 예상치인 413억 9천만 달러, 주당 순이익은 6.43달러로 애널리스트 <a href="https://www.benzinga.com//node/45117948" target="_blank" rel="noopener">예상치 주당 5.21달러</a>를 상회했다.</li>
<li>메타는 2분기 매출을 425억 달러에서 455억 달러로 예상한 반면, <a href="http://pro.benzinga.com/" target="_blank" rel="noopener">벤징가 프로</a> 예상치는 440억 6천만 달러이다.</li>
<li>골드만삭스 <a href="https://www.benzinga.com/quote/META/analyst-ratings" target="_blank" rel="noopener">애널리스트</a> 에릭 셰리던은 마크 저커버그 CEO가 제시한 5가지 AI 기반 기회로 향상된 광고, 더욱 매력적인 사용자 경험, 비즈니스 메시징, 메타 AI, AI 기기, 특히 전년 대비 3배 매출과 4배 이상의 활성 사용자 수를 기록한 레이밴 메타 AI 글라스를 꼽았다.</li>
<li>뱅크오브아메리카 증권 애널리스트들은 메타가 거시 경제 환경이 완화된 상황에서 번창할 수 있는 좋은 위치에 있다고 보고 있으며, 회사의 자본 지출에 대해 "<a href="https://www.benzinga.com/25/05/45144725/meta-analysts-highlight" target="_blank" rel="noopener">장기적인 성장을 위한 기반 구축</a>"이라고 강조했다.</li>
<li>니덤 애널리스트인 로라 마틴은 메타가 유통이나 콘텐츠를 통제하지 못하고 애플, 틱톡, 유튜브와 치열한 경쟁에 직면해 있다는 점을 지적하며 회사의 장기적인 잔존 가치(terminal value)에 의문을 제기했다.</li>
</ul>
마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): 댄 롭은 마이크로소프트에 대한 지분을 2024년 3분기 87만 주에서 <a href="https://www.benzinga.com/news/large-cap/25/03/44115397/dan-loebs-third-point-slashes-microsoft-stake-analysts-blame-disappointing-azure" target="_blank" rel="noopener">4분기 60만 주</a>로 줄였다.
<ul>
<li>마이크로소프트는 3분기 매출이 700억 7천만 달러로 월가 컨센서스 예상치 684억 3천만 달러를 상회했고, EPS는 3.46달러로 <a href="https://www.benzinga.com//node/45117886" target="_blank" rel="noopener">월가 컨센서스 추정치 3.22달러</a>를 상회했다고 보고했다.</li>
<li>마이크로소프트는 클라우드 서비스와 고객 중심 솔루션에 대한 집중이 경기 침체에서 살아남을 뿐만 아니라 이를 통해 성장할 수 있다고 말했다.</li>
<li>마이크로소프트는 4분기 클라우드 마진을 약 67%로 예상했으며, 인텔리전트 클라우드 매출은 287억 5천만 달러에서 290억 5천만 달러 사이로 예상했다.</li>
<li>골드만삭스 애널리스트 카시 랑간(Kash Rangan)은 거시 경제의 불확실성과 잠재적 관세 위험에도 불구하고 2026회계연도에 3%의 잉여현금흐름 성장과 17%의 주당 순이익 성장을 기록할 것이며, <a href="https://www.benzinga.com//node/45137383" target="_blank" rel="noopener">애저는 30%의 성장률을 유지</a>할 것으로 전망했다.</li>
<li>키뱅크 애널리스트 잭슨 애더는 마이크로소프트의 AI 투자 수익 구조가 여전히 이해하기 어렵고, <a href="https://www.benzinga.com//node/45149535" target="_blank" rel="noreferrer noopener">&#8220;공격적인 전략&#8221;을 취할 수 있는 더 나은 주식이 있을 수 있다</a>고 주장했다.</li>
<li>마이크로소프트가 지원하는 오픈AI는 <a href="https://www.benzinga.com//node/45224667" target="_blank" rel="noopener">AI 기반 코딩 어시스턴트</a> 시장 경쟁에 뛰어들기 위해 윈드서프(Windsurf)를 약 30억 달러에 인수하기로 합의했다.</li>
<li>연초 이후 마이크로소프트는 약 3.12% 상승하여 같은 기간 동안  iShares 미국 기술 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>)는 약 9.93% 하락했다.</li>
</ul>
포티브 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>): 2024년 4분기에 댄 롭은 포티브의 지분 <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noopener">190만 주를 인수</a>했다.
<ul>
<li>포티브는 1분기 조정 EPS가 0.85 달러로 컨센서스와 일치하며, 매출은 14억 7천만 달러로 <a href="https://www.benzinga.com//node/45130994" target="_blank" rel="noopener">컨센서스 14억 9천만 달러를 하회</a>했다고 보고했다.</li>
<li>포티브는 2분기 조정 주당순이익을 0.85~0.90달러로 전망하고 있으며, <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noopener">시장 예상치는 0.98달러</a>다.</li>
<li>퐅티브는 FY25 조정 주당순이익 가이던스를 4.00~4.12달러에서 3.80~4.00달러로 컨센서스인 4.02달러보다 낮췄다.</li>
<li>포티브는 2025년 6월 2일부로 닐 레이놀즈를 랠리언트(Ralliant) CFO로 임명하고 <a href="https://www.benzinga.com//node/45190836" target="_blank" rel="noopener">랠리언트의 분할 계획</a>에 대한 양식 10 등록 명세서를 제출한다고 발표했다.</li>
<li>바클레이즈 애널리스트 줄리안 미첼은 비중확대 등급을 유지하고 목표주가를 85달러에서 84달러로 낮췄다.</li>
<li>포티브의 연초 대비 수익률은 약 10.91% 하락하여 같은 기간 동안 WisdomTree U.S. AI Enhanced Value Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIVL#NYSE">AIVL</a>)는 약 0.04% 하락했다.</li>
</ul>
헤스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>): 서드포인트는 2024년 4분기 기준<a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noopener"> 62만 5천 주를 보유</a>하고 잇다.
<ul>
<li>헤스는 1분기 조정 EPS가 1.81 달러로 컨센서스 추정치 1.61 달러를 상회하고 매출은 29억 4천만 달러로 <a href="https://www.benzinga.com//node/45096392" target="_blank" rel="noopener">예상치 27억 1천만 달러를 초과</a>했다고 발표했다.</li>
<li>헤스는 2분기에 하루 총 생산량을 480~490MBOE, 탐사 및 생산 자본 및 탐사 지출을 12억 7,000만 달러로 예상하고 있다.</li>
<li>올해 들어 헤스 주가는 약 5.07% 하락한 반면 Invesco S&amp;P 500 동일가중 에너지 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPG#NYSE">RSPG</a>)는 같은 기간 동안 약 10.63% 하락했다.</li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아마존·메타·마이크로소프트 실적, '행동주의 헤지펀드' 서드포인트의 포트폴리오에 의미하는 바는?

Comments

WisdomTree U.S. AI Enhanced Value Fund

뉴스

에 대한 최신 뉴스 WisdomTree U.S. AI Enhanced Value Fund (ARCA:AIVL)

수요일, 5월 07, 2025

뉴스

파트너 / 기고자

벤징가 글로벌